Insights & Articles

Explore all Xpeer articles, clinical perspectives, CME trends, and educational content designed for healthcare professionals.

How to optimise HCP engagement strategy through accredited Medical Education

The relationship between healthcare professionals (HCPs) and the pharmaceutical industry is becoming more complex nowadays. Physicians are inundated with information, time-poor, and increasingly cautious about

Written by Xpeer, 11/20/25

Future of medical education: AI, virtual reality and microlearning

Are you ready for the future of medical education?For decades, medical learning meant lectures, long hours and limited hands-on practice. Today, technology is changing that

Written by Xpeer, 11/10/25

Omnichannel Marketing Strategies for Pharma in 2025: Innovating with Events and Digital Content

Discover how pharmaceutical companies can thrive in 2025 by adopting innovative omnichannel marketing strategies. From AI-powered content personalization to TED-style hybrid events, this guide reveals the latest trends, practical steps, and success stories to help you build lasting connections with healthcare professionals. Stay ahead in a competitive and regulated market by mastering omnichannel excellence.

Written by Zayra Otero, 04/28/25

Inaxaplin (VX-147): A First-in-Class Therapy Targeting APOL1-Mediated Kidney Disease

Chronic kidney disease (CKD) remains a significant global health challenge, particularly among individuals with African ancestry. A notable contributor to this disparity is the presence of high-risk variants in the APOL1 gene, which are associated with an increased risk of kidney diseases such as focal segmental glomerulosclerosis (FSGS) and HIV-associated nephropathy. Addressing this unmet medical need, Inaxaplin (VX-147), developed by Vertex Pharmaceuticals, emerges as a promising first-in-class oral therapy specifically targeting APOL1-mediated kidney disease (AMKD).

Written by Zayra Otero, 07/07/25

Lenacapavir: A Breakthrough in HIV Prevention With Just Two Annual Doses

HIV prevention has advanced significantly over the past two decades—from daily oral PrEP to bi-monthly injectable options. Now, Lenacapavir, a long-acting capsid inhibitor developed by Gilead Sciences, is poised to transform the landscape by offering a twice-yearly injection for pre-exposure prophylaxis (PrEP).

Written by Zayra Otero, 07/04/25

Challenges in medical education for the pharma industry

Discover the top 5 challenges in medical education for the pharma industry and strategies to enhance HCP engagement

Written by Daniela Clape, 11/14/24

Digital Transformation In The Pharmaceutical Industry

The Stages and Challenges Of Digital Transformation in Pharma

Written by Daniela Clape, 11/08/24

AI and Machine Learning in Pharma: Redefining Medical Education

The ability to harness AI and ML allows companies to create measurable impacts on healthcare outcomes

Written by Daniela Clape, 12/30/24